美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Atlas Pipeline Partners L.P.

成交量：- -

成交額：- -

市值：- -

市盈率：- -

高：- -

開：- -

低：- -

收：- -

52周最高：- -

52周最低：- -

股本：- -

流通股本：- -

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

直擊調研 | 亞虹醫藥(688176.SH)：APL-1202已於2022年12月完成II期臨床首例受試者入組

亞虹醫藥(688176.SH)：APL-1202口服聯合替雷利珠單抗新輔助治療肌層浸潤性膀胱癌(MIBC)完成II期臨床首例受試者入組

NASA行星防禦背後：撞了顆直徑160米的小行星，耗7年21億元

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/APL"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"APL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APL\",,,,,undefined,":{"symbol":"APL","market":"US","secType":"STK","nameCN":"Atlas Pipeline Partners L.P.","latestPrice":0,"timestamp":0,"preClose":0,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"盤前交易","change":0,"latestTime":"05-19 08:01:17 EDT","open":0,"high":0,"low":0,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1779197400000},"marketStatusCode":1,"adr":0,"exchange":"NYSE","adjPreClose":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"APL\",,,,,undefined,":{"symbol":"APL","floatShares":0,"roa":"--","roe":"--","lyrEps":0,"shares":0,"dividePrice":0,"high":0,"amplitude":0,"preClose":0,"low":0,"week52Low":0,"pbRate":"--","week52High":0,"institutionHeld":0,"latestPrice":0,"eps":0,"divideRate":0,"volume":0,"delay":0,"open":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/APL\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"APL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"APL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"APL\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2308070888","title":"直擊調研 | 亞虹醫藥(688176.SH)：APL-1202已於2022年12月完成II期臨床首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2308070888","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2308070888?lang=zh_tw&edition=fundamental","pubTime":"2023-02-01 11:51","pubTimestamp":1675223481,"startTime":"0","endTime":"0","summary":"APL-1202一线治疗未经治疗的中危NMIBC在持续入组受试者。亚虹医药表示，APL-1202口服联合替雷利珠单抗新辅助治疗肌层浸润性膀胱癌已于2022年12月完成II期临床首例受试者入组。此外，APL-1706于2022年3月获中国国家药品监督管理局药品审评中心批准，纳入药品临床真实世界数据应用试点。营销方面，亚虹医药称，根据海南省“先行先试”的相关规定，继APL-1706落地博鳌后，公司一次性膀胱软镜在2022年8月于海南省人民医院乐城院区完成首次使用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/869571.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","APL","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2290202286","title":"亞虹醫藥(688176.SH)：APL-1202口服聯合替雷利珠單抗新輔助治療肌層浸潤性膀胱癌(MIBC)完成II期臨床首例受試者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2290202286","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2290202286?lang=zh_tw&edition=fundamental","pubTime":"2022-12-12 17:20","pubTimestamp":1670836845,"startTime":"0","endTime":"0","summary":"智通财经APP讯，亚虹医药(688176.SH)公告，公司开展的APL-1202口服联合替雷利珠单抗新辅助治疗肌层浸润性膀胱癌(MIBC)临床试验，于近日完成II期临床试验首例受试者入组。据悉，APL-1202(商品名唯施可®)是一款口服的可逆性MetAP2抑制剂，具有抗血管生成、抗肿瘤活性及调节肿瘤免疫微环境的作用。临床前研究显示，APL1202与PD-1单抗联合用药在膀胱癌药效学模型上显示出协同作用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/845797.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688176","BK0239","APL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2271753099","title":"NASA行星防禦背後：撞了顆直徑160米的小行星，耗7年21億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2271753099","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2271753099?lang=zh_tw&edition=fundamental","pubTime":"2022-09-29 05:57","pubTimestamp":1664402220,"startTime":"0","endTime":"0","summary":"当地时间9月26日，美国国家航空航天局“双小行星重定向测试”航天器成功撞击一颗名为迪莫弗斯的近地小行星。这是世界上首次进行旨在防御地球免遭小行星撞击威胁的任务。　　据美国国家航空航天局电视台 9月27日报道，位于马里兰州劳雷尔的约翰斯·霍普金斯大学应用物理实验室的任务控制中心于美东时间27日19点14分宣布，在太空中飞行10个月后，NASA的DART航天器成功撞击了小行星迪莫弗斯，这是NASA首次尝试在太空中改变小行星运动轨道。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/usstock/c/2022-09-29/doc-imqmmtha9149607.shtml?finpagefr=p_115","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2022-09-29/doc-imqmmtha9149607.shtml?finpagefr=p_115","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APL"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/APL\",params:#limit:6,delay:false,,,undefined,":[]}}